Clinical

A healthcare delivery model that utilizes home visits and that is interdisciplinary and team-based has been shown to improve care while controlling costs for patients with complex needs

The full slides from the 2015 Patient-Centered Diabetes Care keynote speech, where Robert A. Gabbay, MD, PhD, discussed new care models being implemented to improve patient health in the long term.

A new report by the American Cancer Society points to disparities in cancer survival between whites and blacks for certain cancers, although the reasons for these differences remain unconfirmed.

What we're reading, February 23, 2016: drug spending for CVS health plans slowed from 11.8% to 5%; CDC Director Tom Frieden, MD, MPH, talks Zika virus; and an investigation into the HealthCare.gov launch found widespread mismanagement.

The supplemental new drug application submitted by Pfizer, the drug's manufacturer, included phase 3 results from the PALOMA-3 trial.

Risk adjustment for social determinants of health could reduce penalties to children’s hospitals for patient factors that are beyond their control, according to the results of a new study published in JAMA Pediatrics.

The American Journal of Managed Care's co-editor-in-chief A. Mark Fendrick, MD, director of the University of Michigan Center for Value-Based Insurance Design (VBID), is testifying on how the principles of VBID and clinical nuance can contribute to healthcare reform in the US military health system.

What we're reading, February 22, 2016: new legislation proposes placing a 3-year moratorium on advertising newly approved drugs; the prevalence and incidence of stroke among young adults has increased significantly; and more women with breast cancer are choosing outpatient mastectomies.

Support from at least 60 senators during today's procedural vote will ensure a final confirmation vote for Robert Califf, MD, likely Tuesday.

Patients with mental illness can be a very difficult population to treat and programs need to be established that properly meet the health needs of these patients, said Dana Goldman, PhD.

A report card evaluating the healthcare being provided to the aging US population found that the use of evidence-based practices widely varies across the country.

This week's top managed care stories included the release of 7 core sets of quality measures, more evidence that value-based insurance design works to lower costs, and the FDA assigns breakthrough designation to AstraZeneca's PD-L1 inhibitor.

Two studies presented at the ongoing 2016 Multidisciplinary Head and Neck Cancer Symposium report on financial hurdles faced by patients diagnosed with head and neck cancer that result in lifestyle modifications, advanced disease, and worse outcomes.

What we're reading, February 19, 2016: long-term hospice care is weighing on Medicare; both the pope and the World Health Organization suggest women in Zika infected countries have access to contraception; and Texas health official steps down after co-authoring study on Planned Parenthood.

While primary care physicians are incorporating more nurse practitioners and physicians' assistants into patient care teams, there is a lack of incorporation of other healthcare professionals, such as behavioral specialists, psychiatrists, and pharmacists.

A study of decade-long trends in the incidence and mortality rates of patients who develop cardiogenic shock during hospitalization for acute myocardial infarction found a decline in death rates, but not incidence.

A new study, published in Nature Communications, has delineated a mechanism that could help explain the resistance that is emerging with the new immuno-oncology agents such as PD-1 and PD-L1.

Employers can encounter complications with benefit design approaches when it comes to those patients for whom traditional, less-expensive drugs are ineffective, or for those who prefer to have the drugs administered differently, explained Cheryl Larson, BA, vice president of the Midwest Business Group on Health.

What we're reading, February 18, 2016: one-third of clinical trial results are never published; Sandoz challenges rule for notices of biosimilar launches; and hepatitis C combination drug could reduce treatment to just 4 weeks.

Wellness programs that base financial incentives on loss aversion could result in better outcomes, according to a trial of how certain financial incentives impact physician activity among overweight and obese adults.

While patients with chronic obstructive pulmonary disease have a higher risk of stroke than the general population, patients who have frequent exacerbations of their illness actually have a reduced risk of stroke than those with infrequent exacerbations.

A Task Force composed of gastroenterology specialists, with a special interest in colorectal cancer, has released updated recommendations urging post-operative colonoscopy instead of endoscopy to improve survival.

Durvalumab is being developed for the treatment of PD-L1—positive patients with inoperable or metastatic urothelial bladder cancer

What we're reading, February 17, 2016: Pfizer pays to settle Medicaid claims case; needle exchanges will get financial boost with federal funding; and in New Jersey, Chris Christie releases budget that includes steep cuts to hospitals.

Individuals with more than one diagnosis are more likely to report to a primary care physician than to a subspecialty physician.

Whether or not employer wellness programs work remains debated, but the real question to address is whether we are even fighting the right battle.

A collaboration led by CMS and America’s Health Insurance Plans released 7 core sets of quality measures created to reduce complexity, decrease cost burden, and ensure high-quality care.

A noninvasive colorectal cancer screening test manufactured by Exact Sciences, which received CMS coverage within months of its FDA approval, is not included under Humana’s coverage policy

Relatively simple improvements could increase patient satisfaction and potentially improve the important process of imparting patient information during enrollment of cancer patients into clinical trials.

Inhibiting the PIGF/VEGFR-1 signaling regressed tumor growth in obese, but not in lean mice, the author report.